natgillin/translations-raw huggingface dataset:
Not all pack-sizes may be available in your country. 
V vaši državi morda ni na voljo vseh navedenih pakiranj.
This should lead to a reduction in liver damage and an improvement in your liver function. 
To naj bi vodilo do zmanjšanja okvare jeter in izboljšanja v njihovem delovanju.
Do not throw away any medicines in your wastewater or household rubbish. 
Zdravila ne smete odvreči v odpadne vode ali med gospodinjske odpadke.
During treatment with Zeffix patients should be monitored regularly. 
Med zdravljenjem z zdravilom Zeffix je treba bolnike redno nadzirati.
If you are planning to change your HIV treatment, discuss this change with your doctor first. 
Če nameravate spremeniti svoje zdravljenje HIV, se o spremembi najprej posvetujte z zdravnikom.
These events were seen infrequently in clinical studies. 
Ti dogodki v kliničnih študijah niso bili pogosti.
Don't push too hard and squirt the liquid into the back of your throat, or you may choke. 
Ne potisnite premočno in ne brizgnite tekočine v zadnji del žrela, ker se lahko zadušite.
Grunwaldzka 189 60-322 Poznan Poland 
Grunwaldzka 189 60-322 Poznan Poljska
Synthetic yellow and red iron oxides 
sintetični rumeni in rdeči železov oksid
Abnormal Value 
Nenormalna vrednost
Talk to your doctor about the risks and benefits of taking Zeffix during your pregnancy. 
Posvetujte se z zdravnikom glede tveganj in koristi jemanja zdravila Zeffix med vašo nosečnostjo.
Remove the applicator from the adapter. 
Odstranite aplikator z nastavka.
Most events have been self-limited, however fatalities have been observed very rarely (see section 4.4). 
Večina primerov je bilo izoliranih, kljub temu pa so se smrtni primeri pojavili zelo redko (glejte poglavje 4.4).
Delta hepatitis or hepatitis C 
Hepatitis delta ali hepatitis C
Other medicinal products (e.g. ranitidine, cimetidine) are eliminated only in part by this mechanism and were shown not to interact with lamivudine. 
Druga zdravila (npr. ranitidin, cimetidin) se le deloma izločajo s pomočjo tega mehanizma in niso kazala interakcij z lamivudinom.
No patients in either group progressed to cirrhosis. 
Pri nobenem od bolnikov v obeh skupinah ni prišlo do progresije v cirozo.
Don't drive or use machines unless you are sure you're not affected. 
Ne upravljajte z vozili ali stroji, če se ne počutite dobro.
It has a very low potential to decrease mitochondrial DNA content, is not permanently incorporated into mitochondrial DNA, and does not act as an inhibitor of mitochondrial DNA polymerase gamma. 
Ima zelo majhen potencial za zmanjševanje vsebnosti mitohondrijske DNA, v mitohondrijsko DNA se ne vključi permanentno in ne deluje kot zaviralec mitohondrijske DNA polimeraze gama.
• other medicines containing lamivudine, used to treat HIV infection (sometimes called the AIDS virus) 
• ostala zdravila, ki vsebujejo lamivudin, ki se uporablja pri zdravljenju okužbe s HIV (včasih se uporablja izraz virus AIDS-a),
Currently available data are described in sections 4.4 and 5.1 but no recommendation on a posology can be made. 
Na podlagi zadnjih dostopnih podatkov, ki so opisani v poglavjih 4.4 in 5.1 ni mogoče dati priporočil glede odmerjanja.
Lamivudine is well absorbed from the gastrointestinal tract, and the bioavailability of oral lamivudine in adults is normally between 80 and 85 %. 
Lamivudin se iz gastrointestinalnega trakta dobro absorbira, biološka uporabnost peroralno danega lamivudina pri odraslih pa je normalno med 80 in 85 %.
Duration of treatment The optimal duration of treatment is unknown. 
Optimalni čas zdravljenja ni znan.
The results of long term carcinogenicity studies with lamivudine in rats and mice did not shown any carcinogenic potential. 
Rezultati dolgotrajnih študij o kancerogenosti lamivudina pri podganah in miših niso pokazali nobenega kancerogenega potenciala.
Following oral administration, the mean time (tmax) to maximal serum concentrations (Cmax) is about an hour. 
Po peroralnem vnosu je povprečen čas (tmax) do dosežene maksimalne serumske koncentracije (Cmax) približno ena ura.
Interaction studies have only been performed in adults. 
Študije medsebojnega delovanja z drugimi zdravili so bile izvedene le pri odraslih.
No specific signs or symptoms have been identified following such overdose. 
Po takšnem prevelikem odmerjanju specifični znaki ali simptomi niso bili opaženi.
YMDD mutant HBV status 
Status YMDD mutanta HBV
Slowly push the plunger in, allowing time to swallow. 
Bat počasi potiskajte noter, da boste imeli čas pogoltniti.
Creatinine clearance ml/min 
Očistek kreatinina ml/min
With prolonged treatment, regular reassessment is recommended to confirm that continuation of the selected therapy remains appropriate for the patient. 
Med dolgotrajnim zdravljenjem so priporočljive redne ponovne ocene za potrditev, da je nadaljevanje izbranega zdravljenja za bolnika ustrezno.
• lactic acidosis (excess lactic acid in the blood). 
• laktacidoza (presežek mlečne kisline v krvi).
From intravenous studies the mean volume of distribution is 1.3 l/kg. 
Z intravenskimi študijami je bil ugotovljen povprečni volumen porazdelitve 1,3 l/kg.
However, relapse following seroconversion can occur. 
Vendar pa lahko po serokonverziji pride do relapsa.
Due to similarities, Zeffix should not be administered concomitantly with other cytidine analogues, such as emtricitabine. 
Zaradi podobnosti, se Zeffix ne sme dajati sočasno z ostalimi analogi citidina, npr. emtricitabinom.
Detailed information on this medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu 
Podrobne informacije o tem zdravilu so na voljo na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
Transmission of hepatitis B 
Prenos hepatitisa B
Less than 1% of these women have been treated for HBV, whereas the majority was treated for HIV at higher doses and with other concomitant medications. 
Manj kot 1 % teh žensk se je zdravilo zaradi HBV; večina se je zdravila zaradi okužbe z virusom HIV, z večjimi odmerki in sočasno z drugimi zdravili.
Zeffix may make you feel tired, which could affect your ability to drive or use machines. 
Zdravilo Zeffix lahko povzroči utrujenost, kar lahko vpliva na vašo sposobnost upravljanja vozil in strojev.
Improvement in liver function was also seen after one year of therapy. 
Po enem letu zdravljenja so opazili tudi izboljšanje jetrne funkcije.
Reduction of erythrocytes and neutrophil counts were identified as the effects most likely to be of clinical relevance. 
Zmanjšanje števila eritrocitov in nevtrofilcev se je pokazal kot učinek z najverjetnejšo klinično pomembnostjo.
Discard one month after first opening. 
Zavrzite en mesec po prvem odprtju.
7 Put the applicator into your mouth, placing the tip of the applicator against the inside of your cheek. 
7 Položite aplikator v usta tako, da je konica aplikatorja ob notranji strani lica.
Tell your doctor or pharmacist if you're taking, have recently taken or might take any other medicines, including herbal medicines or other medicines you bought without a prescription. 
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo, vključno z zdravili rastlinskega izvora ali drugimi zdravili, ki ste jih kupili brez recepta.
The possibility of interactions with other medicinal products administered concurrently should be considered, particularly when their main route of elimination is active renal secretion via the organic cationic transport system e.g. trimethoprim. 
Treba je upoštevati možnost interakcij z drugimi zdravili, ki se uporabljajo sočasno, še posebno, če je njihova glavna pot izločanja aktivna renalna sekrecija preko organskega kationskega transportnega sistema, npr. trimetoprim.
The frequency categories assigned to the adverse reactions are mainly based on experience from clinical trials including a total of 1,171 patients with chronic hepatitis B receiving lamivudine at 100mg. 
Kategorije pogostnosti, pripisane neželenim učinkom, v glavnem temeljijo na izkušnjah iz kliničnih preskušanj s skupaj 1171 bolniki s kroničnim hepatitisom B, ki so prejemali 100 mg lamivudina.
Zeffix also contains preservatives (parahydroxybenzoates) which may cause allergic reactions (possibly delayed). 
Zdravilo Zeffix vsebuje tudi konzervanse (parahidroksibenzoate), ki lahko povzročijo alergijske reakcije (lahko tudi zapoznele).
4 Turn the bottle upside down. 
4 Obrnite stekleničko navzdol.
3 Insert the applicator (C) firmly into the adapter. 
3 aplikator (C) trdno vstavite v nastavek.
HIV co-infection 
Sočasna okužba z virusom HIV
A modest increase in Cmax (28 %) was observed for zidovudine when administered with lamivudine, however overall exposure (AUC) was not significantly altered. 
Opaženo je bilo zmerno zvečanje Cmax (28 %) zidovudina, če se je uporabljal sočasno z lamivudinom, vendar se celotna izpostavljenost (AUC) ni znatno spremenila.
Leave the adapter in the bottle. 
Nastavek pustite v steklenički.
Patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine. 
Bolniki z redkimi heriditarnimi težavami intolerance za fruktozo, malabsorpcije tipa glukozagalaktoza ali insuficience saharaze-izomaltaze, tega zdravila ne smejo jemati.
Lamivudine has been administered to children and adolescents with compensated CHB in a placebo controlled study of 286 patients aged 2 to 17 years. 
Lamivudin so dajali otrokom in mladostnikom s kompenziranim CHB med s placebom nadzorovano študijo pri 286 bolnikih, starih od 2 do 17 let.
Remember to tell your doctor or pharmacist if you begin taking a new medicine while you're taking Zeffix. 
Ne pozabite povedati zdravniku ali farmacevtu, če boste začeli jemati novo zdravilo, medtem ko jemljete zdravilo Zeffix.
Further results from the trial by YMDD mutant status are summarised in Table 2. 
Nadaljnji rezultati, izhajajoči iz študije pri bolnikih z YMDD mutantom, so povzeti v preglednici 2.
You may need extra check-ups, including blood tests, while you're taking your medication. 
Morda boste med jemanjem tega zdravila potrebovali dodatne kontrole, vključno s preiskavami krvi.
Your doctor will monitor the effectiveness of your treatment with regular blood tests. 
Vaš zdravnik bo z običajnimi krvnimi preiskavami spremljal učinovitost vašega zdravljenja.
ALT elevations (see section 4.4) 
Zelo pogosti zvišanje ALT (glejte poglavje 4.4)
Lamivudine should be used with caution in these patients. 
Pri teh bolnikih je treba lamivudin uporabljati previdno.
Table 3: Post-treatment ALT Elevations in 2 Placebo-Controlled Studies in Adults 
Preglednica 3: Zvišanje ALT po zaključku zdravljenja v dveh s placebom nadzorovanih študijah pri odraslih
Zeffix can be taken with or without food. 
Zdravilo Zeffix lahko vzamete s hrano ali brez nje.
When you stop taking Zeffix your doctor will monitor you for at least four months to check for any problems. 
Ko boste prenehali jemati zdravilo Zeffix, vas bo zdravnik še vsaj štiri mesece nadziral glede kakršnih koli težav.
6 Turn the bottle the right way up. 
6 Obrnite stekleničko v pravilen pokončen položaj.
The efficacy of lamivudine in patients co-infected with Delta hepatitis or hepatitis C has not been established and caution is advised. 
Učinkovitost lamivudina pri bolnikih, ki so sočasno okuženi s hepatitisom delta ali hepatitisom C, ni dokazana in priporoča se previdnost.
Patients experiencing signs of hepatic insufficiency during or post-treatment should be monitored more frequently as appropriate. 
Bolnike z znaki jetrne insuficience med zdravljenjem ali po njem je treba nadzirati pogosteje, kot je to običajno.
Experience in patients with HBeAg negative CHB 
Izkušnje pri HBeAg negativnih bolnikih s CHB
Hepatitis B infection is spread by sexual contact with someone who has the infection, or by transfer of infected blood (for example, by sharing injection needles). 
Okužba s hepatitisom B se prenaša s spolnim stikom z okuženo osebo ali s prenosom okužene krvi (npr. s skupno uporabo injekcijskih igel).
In non-controlled studies, where lamivudine was administered prior to and during transplantation, effective HBV DNA suppression and ALT normalisation was demonstrated. 
V nenadzorovanih študijah, kjer so lamivudin dajali pred ali med transplantacijo, je bila dokazana učinkovita supresija HBV DNA in normalizacija ALT.
Frequencies are defined as: very common ( 1/10), common ( 1/100 to < 1/10), uncommon ( 1/1000 to < 1/100), rare ( 1/10,000 to < 1/1000), very rare (< 1/10,000) and not known (cannot be estimated from the available data). 
Pogostnost je definirana kot: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000) in neznana pogostnost (ni mogoče oceniti iz razpoložljivih podatkov).
• a worsening of liver disease after Zeffix is stopped or during treatment if the hepatitis B virus becomes resistant to Zeffix. 
• poslabšanje jetrnih bolezni v primeru prekinitve jemanja zdravila Zeffix ali med zdravljenjem, če postane virus hepatitisa B odporen proti zdravilu Zeffix.
Lamivudine is an antiviral agent which is active against hepatitis B virus in all cell lines tested and in experimentally infected animals. 
Lamivudin je protivirusna učinkovina, ki učinkuje proti virusu hepatitisa B na vseh testiranih celičnih linijah in pri eksperimentalno okuženih živalih.
Limited data shows lamivudine penetrates the central nervous system and reaches the cerebro-spinal fluid (CSF). 
Omejeni podatki kažejo, da lamivudin prodira v centralni živčni sistem in doseže cerebrospinalno tekočino (CSF - "cerebro-spinal fluid").
Table 1: Dosage of Zeffix in patients with decreased renal clearance. 
Preglednica 1: Odmerjanje zdravila Zeffix pri bolnikih z zmanjšanim ledvičnim očistkom.
Available human data from the Antiretroviral Pregnancy Registry reporting more than 1000 outcomes from first trimester and more than 1000 outcomes from second and third trimester exposure in pregnant women indicate no malformative and foeto/neonatal effect. 
Na voljo so podatki Registra protiretrovirusnih zdravil med nosečnostjo (Antiretroviral Pregnancy Registry), ki zajemajo izpostavljenost več kot 1000 izidov nosečnic v prvem trimesečju in več kot 1000 izidov nosečnic v drugem in tretjem trimesečju in ne kažejo malformacijskih učinkov ali učinkov na plod ali novorojenčka.
The total amount of lamivudine ingested by a breastfed infant is very low and is therefore likely to result in exposures exerting a sub-optimal antiviral effect. 
Celotna količina lamivudina, ki ga zaužije dojenček, je zelo majhna in zato verjetno povzroči izpostavljenosti katere protivirusni učinek je suboptimalen.
In patients with HIV infection, cases of pancreatitis and peripheral neuropathy (or paresthesia) have been reported. 
Pri bolnikih, okuženih z virusom HIV, so poročali o primerih pankreatitisa in periferne nevropatije (ali parestezije).
Patients should be advised that therapy with lamivudine has not been proven to reduce the risk of transmission of hepatitis B virus to others and therefore, appropriate precautions should still be taken. 
Bolnikom je treba razložiti, da ni dokazano, da bi zdravljenje z lamivudinom zmanjšalo tveganje za prenos virusa hepatitisa B na druge, tako da so še vedno potrebni ustrezni varnostni ukrepi.
Adverse reactions are listed below by system organ class and frequency. 
Neželeni učinki so našteti spodaj glede na organski sistem in pogostnost.
When doses below 100 mg are required Zeffix oral solution should be used (see Table 1 below). 
Če so potrebni odmerki manjši od 100 mg, je treba uporabiti zdravilo Zeffix peroralno raztopino (glejte preglednico 1 spodaj).
Not everyone responds to treatment with Zeffix in the same way. 
Na zdravljenje z zdravilom Zeffix se ne odzove vsak človek enako.
As the in vitro mutagenic activity of lamivudine could not be confirmed by in vivo tests, it is concluded that lamivudine should not represent a genotoxic hazard to patients undergoing treatment. 
Ker se in vitro mutagene aktivnosti lamivudina z in vivo testi ni dalo potrditi, se sklepa, da lamivudin med zdravljenjem bolnikov ne bi smel predstavljati genotoksičnega tveganja.
In assays relating to potential substance effects on mitochondrial structure and DNA content and function, lamivudine lacked appreciable toxic effects. 
V testiranjih potencialnih vplivov učinkovine na mitohondrijsko strukturo, vsebnost in funkcijo DNA, lamivudin ni imel znatnih toksičnih učinkov.
Lamivudine was not genotoxic in vivo at doses that gave plasma concentrations around 60-70 times higher than the anticipated clinical plasma levels. 
Lamivudin in vivo ni bil genotoksičen pri odmerkih, s katerimi so bile dosežene v plazmi približno 60do 70-krat večje koncentracije od pričakovanih kliničnih plazemskih koncentracij.
Hepatitis B is a virus which infects the liver, causes long term (chronic) infection, and can lead to liver damage. 
Virus hepatitisa B je virus, ki okuži jetra, povzroči dolgotrajno (kronično) okužbo in lahko vodi v okvaro jeter.
Animal studies with lamivudine showed an increase in early embryonic deaths in rabbits but not in rats (see section 5.3). 
Študije na živalih z lamivudinom so pokazale porast zgodnjih smrti zarodkov pri kuncih, toda ne pri podganah (glejte poglavje 5.3).
It is also only a weak inhibitor of mammalian DNA polymerases alpha and beta. 
Prav tako je le šibek zaviralec DNA polimeraz alfa in beta pri sesalcih.
Some people taking Zeffix or other similar medicines are more at risk of serious side effects. 
Nekateri ljudje, ki jemljejo zdravilo Zeffix ali druga podobna zdravila, so bolj ogroženi zaradi resnih neželenih učnikov.
Accidentally taking too much Zeffix is unlikely to cause any serious problems. 
Če po nesreči vzamete prevelik odmerek zdravila Zeffix, je malo verjetno, da bi prišlo do kakršnihkoli resnih težav.
Zeffix can be used in people whose liver is damaged, but still functions normally (compensated liver disease) and in combination with other medicines in people whose liver is damaged and does not function normally (decompensated liver disease). 
Zdravilo Zeffix se lahko uporablja pri osebah, ki imajo okvarjena jetra, vendar jim jetra še vedno normalno delujejo (kompenzirana bolezen jeter), in v kombinaciji z drugimi zdravili pri osebah, ki imajo okvarjena jetra in jim ta ne delujejo normalno (dekompenzirana bolezen jeter).
Serum ALT and HBV DNA levels should be monitored at 3 month intervals and in HBeAg positive patients HBeAg should be assessed every 6 months. 
Serumske vrednosti ALT in HBV DNA vrednosti je potrebno preveriti vsake 3 mesece in pri HBeAg pozitivnih bolnikih pa je HBeAg potrebno preveriti vsakih 6 mesecev.
In a retrospective study to determine the factors associated with HBV DNA breakthrough, 159 Asian HBeAg-positive patients were treated with lamivudine and followed up for a median period of almost 30 months. 
V retrospektivni študiji za ugotovitev dejavnikov, povezanih s ponovnim povečanjem HBV DNA, je bilo 159 azijskih HBeAg-pozitivnih bolnikov, ki so se zdravili z lamivudinom in so jih spremljali mediano skoraj 30 mesecev.
This population primarily consisted of children with minimal hepatitis B. A dose of 3 mg/kg once daily (up to a maximum of 100 mg daily) was used in children aged 2 to 11 years and a dose of 100 mg once daily in adolescents aged 12 years and above. 
Populacija je bila v glavnem sestavljena iz otrok z minimalnim hepatitisom B. Otroci, stari od 2 do 11 let, so jemali odmerek 3 mg/kg enkrat dnevno (do največjega odmerka 100 mg dnevno), mladostniki, stari 12 let in več, pa so jemali odmerek 100 mg enkrat dnevno.
Frequency categories are only assigned to those adverse reactions considered to be at least possibly causally related to lamivudine. 
Kategorije pogostnosti so omejene le na tiste neželene učinke, za katere obstaja vsaj možna vzročna povezava z lamivudinom.
The requirements for submission of periodic safety update reports for this medicinal products are set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal. 
Zahteve glede predložitve rednega posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov EU (seznam EURD), opredeljenem v členu 107c(7)
A side effect which may show up in blood tests is: • a decrease in the number of cells involved in blood clotting (thrombocytopenia). 
Neželeni učinek, ki se lahko pokaže pri preiskavah krvi, je: • zmanjšanje števila celic, ki sodelujejo pri strjevanju krvi (trombocitopenija).
At the end of 5 years, all patients had HBV DNA levels that were undetectable or lower than pre-treatment levels. 
Po preteku 5 let so bile pri vseh bolnikih ravni HBV DNA nezaznavne ali nižje v primerjavi s stanjem pred zdravljenjem.
What Zeffix is and what it is used for 2. 
Kaj je zdravilo Zeffix in za kaj ga uporabljamo 2.
If you take more Zeffix than you should 
Če ste vzeli večji odmerek zdravila Zeffix, kot bi smeli
5 to < 15 
5 do < 15
If you are already taking another medicine that contains lamivudine for HIV infection, your doctor will continue to treat you with the higher dose, (usually 150 mg twice a day), because the dose of lamivudine in Zeffix (100 mg) is not enough to treat HIV infection. 
Če že jemljete kakšno drugo zdravilo, ki vsebuje lamivudin, za zdravljenje okužbe s HIV, vas bo zdravnik še naprej zdravil z višjim odmerkom (po navadi 150 mg dvakrat na dan), ker odmerek lamivudina v zdravilu Zeffix (100 mg) ne zadošča za zdravljenje okužbe s HIV.
Treatment with Zeffix can reduce the amount of hepatitis B virus in your body. 
Zdravljenje z zdravilom Zeffix lahko zmanjša količino virusa hepatitisa B v vašem telesu.
30 to < 50 
30 do < 50
For lamivudine-treated patients, the majority of post-treatment ALT elevations occurred between 8 and 12 weeks post-treatment. 
Bolnikom, zdravljenim z lamivudinom, se je večina zvišanj ALT po zdravljenju pojavila od 8 do 12 tednov po zdravljenju.
Herts SG12 0DJ United Kingdom or 
Herts SG12 0DJ Velika Britanija ali
Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino ali za katerokoli pomožno snov, navedeno v poglavju 6.1.
The incidence of YMDD mutant HBV was similar to that observed in adults, ranging from 19 % at week 52 up to 45 % in patients treated continuously for 24 months. 
Pojavnost YMDD mutanta HBV je bila podobna tisti, ki so jo opazili pri odraslih, v obsegu od 19 % v 52. tednu do 45 % pri bolnikih, ki so se kontinuirano zdravili 24 mesecev.
Elevations of CPK 
Pogosti zvišanje CPK
10 Close the bottle tightly with the cap. 
10 Stekleničko tesno zaprite z zaporko.
Some clinical findings also support a possible interaction between lamivudine and cladribine. 
Tudi nekateri klinični izsledki potrjujejo možno medsebojno delovanje med lamivudinom in kladribinom.
When full, the applicator contains 10 ml of solution. 
Ko je aplikator poln, vsebuje 10 ml raztopine.
The mean systemic clearance of lamivudine is approximately 0.3 l/h/kg. 
Povprečni sistemski očistek lamivudina je približno 0,3 l/h/kg.
YMDD1 Non-YMDD1 
Brez YMDD1
Patients should be informed that malaise and fatigue have been reported during treatment with lamivudine. 
Bolnike je potrebno obvestiti, da so med zdravljenjem z lamivudinom poročali o slabem počutju in utrujenosti.
At the highest dosage levels, minor effects on indicators of liver and kidney function were seen together with occasional reduction in liver weights. 
Pri največjih odmerkih so bili opaženi manjši učinki na pokazatelje jetrne in ledvične funkcije ter občasno zmanjšanje teže jeter.
The intracellular half life of the triphosphate in hepatocytes is 17-19 hours in vitro. 
In vitro je znotrajcelični razpolovni čas trifosfata v hepatocitih od 17 do 19 ur.
Exacerbations after treatment discontinuation 
Poslabšanja po prenehanju zdravljenja